Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc has demonstrated a significant increase in the probability of regulatory approval for its lead candidate RP1 in combination with Opdivo for anti-PD1 failed melanoma patients, rising from 50% to an impressive 85%. The company reports a relatively low incidence of serious treatment-related adverse events, with only 12.8% of patients experiencing G3+ TRAEs, indicating a favorable safety profile for the therapy. Additionally, promising results from the IGNYTE trial further support the potential for approval, bolstering the company's outlook amidst competitive therapies that have shown lower overall response rates.

Bears say

Replimune Group Inc. faces significant risks related to its clinical programs, particularly for the RP1 product candidate, with concerns about the inability to generate compelling efficacy and safety data in future trials and failure to meet FDA requirements for marketing authorization resubmission. Additionally, the FDA's complete response letter (CRL) highlights critical issues with the adequacy of the IGNYTE trial, the heterogeneity of the patient population, and insufficient data to support key statistical endpoints, which could hinder regulatory approval. Furthermore, the potential for medium- to long-term dilution poses an additional financial risk that may impact investor sentiment and the company's valuation.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.